Search results

Selected filters:

Law & Policy

Article type

Topic

Sector

Regions

2,348 results found for your search

Sort options
14 February 2019

As 101 debate continues, Iancu offers clear message to Federal Circuit

With new guidelines set to reshape patent examination, the USPTO head makes the case for revisiting subject matter precedent

13 February 2019

IPBC Global 2019 is shaping up to be the biggest and best of the series so far

Senior decision makers from a wide range of companies are already confirmed to attend as demand for tickets exceeds the rate for last year's sell-out event in San Francisco 

11 February 2019

Huawei owns the future and that’s why it’s here to stay

Deep pockets, a strong commitment to R&D and a world class 5G patent portfolio mean that whatever its current difficulties the Chinese telecoms business is set to be a major player for the long term

09 February 2019

The big life sciences patent developments in January

Record-breaking Celgene purchase, two decisions on the on-sale bar, Europe moves towards SPC manufacturing waiver, China proposes five-year patent term extension and much more

08 February 2019

US patent system jumps to second in the world, though the biopharma sector may not agree

PTAB reforms help fuel a miraculous rise up the latest International IP Index, but a recent Federal Circuit decision on eligibility highlights the serious challenges that remain - especially for life sciences companies

05 February 2019

USPTO rules on patent term adjustment set to change following CAFC decision

The Federal Circuit’s precedential judgment in Supernus Pharmaceuticals v Iancu is good news for rights holders – especially those in life sciences

01 February 2019

We have not been informed of any Chinese antitrust investigation of us, Ericsson tells <em>IAM</em>

Swedish company issues statement after an unsourced Chinese media article claims that a probe into its licensing practices is underway

31 January 2019

Critical condition: why patents matter more than ever for medical devices

From uncertainty over patent eligibility to the forces of convergence increasingly shaping the sector, IP strategy has never been more important for medical device companies.

31 January 2019

The pharma fightback

Brand name pharmaceutical companies are facing a policy-making onslaught; with their IP strategies firmly in the spotlight, many are being forced to speak up for the rights that underpin their products.

31 January 2019

Pressure piles on US pharma and biotech IP owners

America's life sciences innovators face accusations of using patents to build monopolies and overcharge for vital medicines. If they do not tell their side of the story and fast, they risk losing vital protections on which they rely   

30 January 2019

<em>Arrow</em> declarations: exploiting court flexibility to clear a path to market

When it comes to litigation strategy, drug businesses have another option to consider in some cases thanks to recent rulings from the courts of England and Wales.

30 January 2019

IP monetisation: what might the future hold?

For years much of the focus on creating value from intellectual property has been on patents, but the emergence of a group of new technologies may help to rewrite the rules on monetisation. Patents will still play a crucial role but look set to become part of a broader mix of intangible assets in the discussion around value creation.

28 January 2019

Critical condition: has Section 101 put the US medical device sector on life support?

As fears grow over subject-matter eligibility and technological convergence threatens to reshape the competitive landscape, patent strategy has become even more crucial for medical device companies

25 January 2019

Treat IP rights as property to maximise their value, Huawei CEO urges

In a rare public appearance, the Chinese telecom’s founder and CEO, Ren Zhengfei, reaffirms commitment to respect third-party patents and explains why paying more than the competition will keep his company ahead

25 January 2019

SCOTUS ruling is a blow to small companies on the frontline of life sciences innovation

The court’s decision in Helsinn Healthcare v Teva Pharmaceutical will disappoint the many biopharma businesses that depend on pre-marketing drug development collaboration